relatively short follow-up, the low sample size and the long-lasting response to the adalimumab originator at the time of the shift for many patients, the results are in line with previous comparability studies 1,3,4,5 and demonstrate that the biosimilar adalimumab has shown not to be less effective than the originator and the transition to biosimilar adalimumab in psoriasis patients treated with the originator is a safe and effective choice in a real-life setting of moderate to severe psoriasis patients as previously observed in other biologic treatments, in particular infliximab. 6 The only difference we observed was a significant worsening of the assessment of pain in a subpopulation of patients with BMI> 25 between T0 and T1 suggesting the need of further evaluations and objective data, also with a multi-specialist team.

Background Many therapeutic modalities are available for treating genital warts; however, the effectiveness of both diphenylcyclopropenone and podophyllin is still controversial. Aim To evaluate the effectiveness and safety of diphenylcyclopropenone and podophyllin in treating genital warts. Methods This study included 57 patients, divided randomly into two groups. Group (A): diphenylcyclopropenone ( n = 29). Group (B): podophyllin 25% ( n = 28). In group (A), sensitization was done with 2% diphenylcyclopropenone. Then, after 1 or 2 weeks, treatment started with a weekly application of diphenylcyclopropenone solutions ranging between 0.001 and 1% until clearance, or for a maximum of 10 sessions. In group (B), podophyllin 25% was applied weekly until clearance or for a maximum of 6 weeks. Results Higher clearance was achieved in group A, with 19 of 29 (65.5%) patients, than in group B, with 9 of 28 (32.1%) ( p-value = 0.004). Also, effectiveness increases with young age in group A. Shorter wart duration was associated with better response in both groups ( p-value = 0.005). No serious adverse effects occurred in either group. No recurrence was detected in group A, while seven patients (77.8%) had recurrence in group B after 1 year of follow up. Conclusion Diphenylcyclopropenone shows a higher success rate than podophyllin in treating genital warts and a lower recurrence rate.